Literature DB >> 18077491

Mural inflammatory hyperenhancement in MRI of giant cell (temporal) arteritis resolves under corticosteroid treatment.

T A Bley1, M Markl, M Schelp, M Uhl, A Frydrychowicz, P Vaith, H-H Peter, M Langer, K Warnatz.   

Abstract

OBJECTIVE: To determine the effect of corticosteroid treatment on mural inflammatory hyperenhancement in MRI in GCA.
METHODS: MRI of the superficial temporal artery with sub-millimetre in-plane spatial resolution (195 x 260 microm) was performed in 17 patients with proven GCA at the initiation of corticosteroid treatment and after 16 months of therapy. Visual MRI scores for mural inflammation were correlated with clinical and laboratory findings.
RESULTS: Intensity of inflammatory hyperenhancement decreased significantly under corticosteroid therapy (2.3 +/- 0.6 vs 0.5 +/- 0.6, P < 0.001, with MRI score >2 indicating vasculitis). This finding correlated with the clinical and serological remission in 15/17 patients. Of the two patients with active disease, one had persisting mural inflammation in MRI indicative of relapsing disease. The other patient presenting with signs of polymyalgia rheumatica had no inflammatory changes of the superficial temporal arteries on MRI scan at follow-up.
CONCLUSIONS: Mural contrast enhancement in high-resolution MRI is pronounced in active disease and decreases under corticosteroid treatment, correlating well with laboratory remission.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18077491     DOI: 10.1093/rheumatology/kem283

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  14 in total

1.  [Magnetic resonance angiography in rheumatology].

Authors:  T A Bley; B Ostendorf; A Scherer; H Kellner; W A Schmidt
Journal:  Z Rheumatol       Date:  2012-07       Impact factor: 1.372

Review 2.  [Imaging techniques for giant cell arteritis. Ultrasound and MRI].

Authors:  M Reinhard; W A Schmidt; A Hetzel; T A Bley
Journal:  Z Rheumatol       Date:  2009-03       Impact factor: 1.372

Review 3.  [Imaging techniques in the evaluation of primary large vessel vasculitides: part 1: angiography, interventional therapy, and magnetic resonance imaging].

Authors:  M Both; B Nölle; C von Forstner; F Moosig; W L Gross; M Heller
Journal:  Z Rheumatol       Date:  2009-08       Impact factor: 1.372

Review 4.  The diagnosis and treatment of giant cell arteritis.

Authors:  Thomas Ness; Thorsten A Bley; Wolfgang A Schmidt; Peter Lamprecht
Journal:  Dtsch Arztebl Int       Date:  2013-05-24       Impact factor: 5.594

5.  Increased diagnostic accuracy of giant cell arteritis using three-dimensional fat-saturated contrast-enhanced vessel-wall magnetic resonance imaging at 3 T.

Authors:  Guillaume Poillon; Adrien Collin; Ygal Benhamou; Gaëlle Clavel; Julien Savatovsky; Cécile Pinson; Kevin Zuber; Frédérique Charbonneau; Catherine Vignal; Hervé Picard; Tifenn Leturcq; Sébastien Miranda; Thomas Sené; Emmanuel Gerardin; Augustin Lecler
Journal:  Eur Radiol       Date:  2019-12-06       Impact factor: 5.315

Review 6.  Imaging in Giant Cell Arteritis.

Authors:  Asad Khan; Bhaskar Dasgupta
Journal:  Curr Rheumatol Rep       Date:  2015-08       Impact factor: 4.592

Review 7.  Neuro-ophthalmic complications in giant cell arteritis.

Authors:  Frances A Borg; Victoria L J Salter; Bhaskar Dasgupta
Journal:  Curr Allergy Asthma Rep       Date:  2008-07       Impact factor: 4.806

Review 8.  An approach to the diagnosis and management of systemic vasculitis.

Authors:  A Miller; M Chan; A Wiik; S A Misbah; R A Luqmani
Journal:  Clin Exp Immunol       Date:  2010-01-12       Impact factor: 4.330

9.  [Large-vessel vasculitis. Imaging and interventional therapy].

Authors:  M Both; F Moosig; W L Gross; M Heller
Journal:  Radiologe       Date:  2009-10       Impact factor: 0.635

10.  3D-black-blood 3T-MRI for the diagnosis of thoracic large vessel vasculitis: A feasibility study.

Authors:  Karla Maria Treitl; Stefan Maurus; Nora Narvina Sommer; Hendrik Kooijman-Kurfuerst; Eva Coppenrath; Marcus Treitl; Michael Czihal; Ulrich Hoffmann; Claudia Dechant; Hendrik Schulze-Koops; Tobias Saam
Journal:  Eur Radiol       Date:  2016-08-10       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.